cached image

Pavan K. Auluck, MD PhD - Publications

Affiliations: 
Pathology Massachusetts Institute of Technology and Harvard Medical School and Masssachusetts General Hospital, Boston, MA, United States 
Area:
models of neurodegenerative disease

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck P, Montrasio F, Nitsch RM, Hirst WD, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiology of Disease. PMID 30381260 DOI: 10.1016/j.nbd.2018.10.016  0.321
2017 Chung CY, Khurana V, Yi S, Sahni N, Loh KH, Auluck PK, Baru V, Udeshi ND, Freyzon Y, Carr SA, Hill DE, Vidal M, Ting AY, Lindquist S. In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons. Cell Systems. PMID 28131823 DOI: 10.1016/J.Cels.2017.01.002  0.689
2017 Khurana V, Peng J, Chung CY, Auluck PK, Fanning S, Tardiff DF, Bartels T, Koeva M, Eichhorn SW, Benyamini H, Lou Y, Nutter-Upham A, Baru V, Freyzon Y, Tuncbag N, et al. Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways. Cell Systems. PMID 28131822 DOI: 10.1016/J.Cels.2016.12.011  0.676
2014 Caraveo G, Auluck PK, Whitesell L, Chung CY, Baru V, Mosharov EV, Yan X, Ben-Johny M, Soste M, Picotti P, Kim H, Caldwell KA, Caldwell GA, Sulzer D, Yue DT, et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. Proceedings of the National Academy of Sciences of the United States of America. 111: E3544-52. PMID 25122673 DOI: 10.1073/Pnas.1413201111  0.567
2013 Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (New York, N.Y.). 342: 983-7. PMID 24158904 DOI: 10.1126/Science.1245296  0.704
2011 di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Research. 71: 19-28. PMID 21199795 DOI: 10.1158/0008-5472.Can-10-2602  0.656
2010 Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annual Review of Cell and Developmental Biology. 26: 211-33. PMID 20500090 DOI: 10.1146/Annurev.Cellbio.042308.113313  0.596
2010 Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Disease Models & Mechanisms. 3: 194-208. PMID 20038714 DOI: 10.1242/Dmm.004267  0.731
2009 Steele AD, Zhou Z, Jackson WS, Zhu C, Auluck P, Moskowitz MA, Chesselet MF, Lindquist S. Context dependent neuroprotective properties of prion protein (PrP). Prion. 3: 240-9. PMID 19901559 DOI: 10.4161/Pri.3.4.10135  0.7
2009 Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan JS, Karger DR, Lindquist S, Fraenkel E. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nature Genetics. 41: 316-23. PMID 19234470 DOI: 10.1038/Ng.337  0.681
2009 Scheithauer BW, Swearingen B, Whyte ET, Auluck PK, Stemmer-Rachamimov AO. Ependymoma of the sella turcica: a variant of pituicytoma. Human Pathology. 40: 435-40. PMID 18992914 DOI: 10.1016/J.Humpath.2008.08.013  0.48
2008 di Tomaso E, Frosch MP, Auluck PK, Cahill D, Duda DG, Plotkin SR, Loeffler JS, Sorensen AG, Batchelor TT, Jain RK. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment Journal of Clinical Oncology. 26: 2009-2009. DOI: 10.1200/Jco.2008.26.15_Suppl.2009  0.5
2005 Auluck PK, Meulener MC, Bonini NM. Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. The Journal of Biological Chemistry. 280: 2873-8. PMID 15556931 DOI: 10.1074/jbc.M412106200  0.7
2002 Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nature Medicine. 8: 1185-6. PMID 12411925 DOI: 10.1038/nm1102-1185  0.559
2002 Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (New York, N.Y.). 295: 865-8. PMID 11823645 DOI: 10.1126/Science.1067389  0.668
Show low-probability matches.